News

ALS Association helping to move ORY-4001 into animal studies

The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…

ALS/MND 2023: Gout med fails to show efficacy in small trial

Colchicine, an anti-inflammatory medication used to treat gout, was safe, but did not significantly slow the progression of amyotrophic lateral sclerosis (ALS) in a small Phase 2 clinical trial. While some clinical measures suggested a possible benefit of a low dose of colchicine in slowing disease progression and extending…

ALS/MND 2023: AMX0114 may enter clinical testing next year

Amylyx Pharmaceuticals is developing AMX0114, a new experimental treatment for amyotrophic lateral sclerosis (ALS) that’s designed to promote the health of nerve fibers by lowering levels of calpain-2, a protein. AMX0114 is being tested in preclinical studies with the aim of supporting an investigational new drug application (IND),…